Tamtam Try Tamtam free
Amneal Pharmaceuticals logo

Amneal Pharmaceuticals account plan

Affordable access essential medicines

At a glance

Amneal Pharmaceuticals makes complex generics, biosimilars and specialty drugs, with $3,018.8 million of 2025 revenue and over 8,500 employees.

Amneal Pharmaceuticals (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, develops, manufactures and distributes generic, injectable, biosimilar and branded medicines, operating principally in the U.S., India and Ireland. It has about 300 complex generic, specialty and biosimilar medicines and delivers more than 160 million prescriptions a year, mainly in the United States. FY2025 net revenue was $3,018.8 million (+8.0%), operating income $394.1 million and net income $127.9 million. It had over 8,500 employees at end-2025, excluding about 200 at AvKARE. Co-founders Chirag Patel and Chintu Patel are Co-CEOs; four wholesalers and pharmacies (Cencora, McKesson, Cardinal Health, CVS Health) were about 71% of revenue.

Business units

Strategic priorities

Biosimilars as main growth driver
With Kashiv closed, Amneal has end-to-end biosimilar capabilities and over 20 biosimilar programs; biosimilars are expected to drive most growth toward a 2030 revenue target of $4.3-$4.5 billion.
Complex generics and injectables
Launches include women's health transdermal patches, lanreotide (30%-40% share targeted), romidepsin and iohexol, with a next wave of sterile injectables and bag products in 2027-2029 and five more inhalation approvals targeted over three years.
Grow Specialty brands
CREXONT adds around 400 new prescribers a month and Amneal aims to make it first-line therapy; BREKIYA is ahead of expectations; M&A focus turns to CNS and oncology assets.
U.S. manufacturing expansion
Capacity is being added for women's health patches, U.S. sterile injectables by 2028, two GLP-1 facilities for the Pfizer collaboration and biosimilar drug substance, from about 26,000 liters to about 75,000 liters by 2028.
Deleveraging
Net leverage was 3.0x at Q3 2026, expected at 3.6x at year-end and below 3x by 2028.

Latest results

In Q3 2026 (quarter to September 30, 2026) net revenue rose 10.0% to $862.7 million, with Affordable Medicines up 18.7% and Specialty up 20.0%, while AvKARE fell 16.7%. Operating income rose 35.6% to $95.4 million, but the GAAP net loss attributable to Amneal was $22 million because of acquisition costs and a higher tax provision. Adjusted EBITDA rose 30% to $207 million. FY2026 guidance was raised to net revenue of $3.15-$3.25 billion and adjusted EBITDA of $800-$815 million, while operating cash flow guidance was cut to $325-$375 million on higher inventory.

Investments and deals

Kashiv BioSciences acquisition
Closed August 10, 2026 for a preliminary $1.3 billion: $375.0 million cash and 28.9 million shares, up to $350.0 million of milestones and royalties; $400-$500 million of financial benefits are expected.
Capital expenditure
2026 capex guidance was raised from about $110 million to about $150 million for women's health demand and U.S. injectable expansion.
GLP-1 facilities for Pfizer
Amneal is building API and fill-finish facilities in India, with construction completing late 2028 to 2029; Metsera, acquired by Pfizer, funds up to $100 million.
Injectables partnerships
A 15-year ApiJect collaboration installs blow-fill-seal equipment at Brookhaven, New York, which was selected for the FDA PreCheck pilot programme.
Financing
An extra $350.0 million was added to the Term Loan Due 2032 for Kashiv; total indebtedness was $2.7 billion at end-2025.

Challenges and risks

Generic price erosion and RYTARY generics
Generic competition brings volume and price erosion, and multiple RYTARY generics are expected.
Customer concentration
Four customers accounted for about 71% of 2025 revenue.
Tariffs on pharmaceutical imports
A preliminary proposal keeps generic imports tariff-free through July 31, 2028, then 100% for one year and 200% after, which could raise costs of products made outside the U.S., including India.
Leverage and integration risk
Kashiv raised indebtedness and exposure to biosimilar development and launch risks; net leverage is expected at 3.6x at end-2026.
Operational and legal events
July 2026 flooding at an Indian plant cost $5.4 million; the nationwide opioid settlement and an $8.0 million charge for government investigations weigh on results.

What leadership says

“Amneal now has the end-to-end capabilities to succeed in biosimilars”

Chirag Patel, Co-Founder, President and Co-CEO · Q3 2026 earnings call, November 3, 2026

“to become America's number one affordable medicines company and a leading provider of essential medicines globally”

Chirag Patel, Co-Founder, President and Co-CEO · Q3 2026 earnings call, November 3, 2026

“Amneal is in the midst of the most transformative period in our company's history.”

Chirag Patel, Co-Founder, President and Co-CEO · Q2 2026 earnings call, July 30, 2026

“Complex generics build this company, and we are not slowing down.”

Chintu Patel, Co-Founder and Co-CEO · Q3 2026 earnings call, November 3, 2026

Where a supplier can help

Biologics manufacturing capacity
Tied to the biosimilars priority and the drug substance expansion: bioprocess equipment, single-use systems and CDMO support for scaling capacity by 2028.
Sterile injectable and patch production
Tied to the U.S. manufacturing expansion: fill-finish, packaging and automation suppliers fit new sterile and transdermal capacity.
Supply chain and tariff planning
Tied to the tariff challenge: sourcing, trade compliance and API dual-sourcing services for products made in India.
Integration and digital operations
Tied to the Kashiv integration and the digitization of 20 facilities: ERP, quality systems and AI tools for manufacturing efficiency.
Specialty commercial support
Tied to the Specialty priority: prescriber targeting, market access and patient programmes for CREXONT and BREKIYA.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Amneal Pharmaceuticals?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Amneal Pharmaceuticals

What does Amneal Pharmaceuticals do?

Amneal develops, manufactures and distributes complex generics, injectables, biosimilars and branded CNS and endocrine drugs, and distributes medicines to U.S. government and institutional customers through AvKARE.

What is Amneal's revenue?

FY2025 net revenue was $3,018.8 million, up 8.0%. FY2026 guidance is $3.15-$3.25 billion, and the 2030 target is $4.3-$4.5 billion.

How many employees does Amneal have?

Over 8,500 employees at end-2025, excluding about 200 at AvKARE: nearly 2,500 in the U.S. and over 6,000 outside, mainly in India and Ireland.

Who leads Amneal?

Co-founders Chirag Patel (President and Co-CEO) and Chintu Patel (Co-CEO) lead the company; Anastasios Konidaris is CFO and Paul M. Meister is Chairman.

What is Amneal's strategy?

Amneal focuses on biosimilars, complex generics and injectables, growth of its Specialty brands and U.S. manufacturing expansion, aiming to become America's number one affordable medicines company.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)